Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · Real-Time Price · USD
46.13
-1.29 (-2.72%)
At close: Feb 21, 2025, 4:00 PM
46.50
+0.37 (0.80%)
After-hours: Feb 21, 2025, 5:42 PM EST
Soleno Therapeutics Employees
Soleno Therapeutics had 33 employees as of December 31, 2023. The number of employees increased by 8 or 32.00% compared to the previous year.
Employees
33
Change (1Y)
8
Growth (1Y)
32.00%
Revenue / Employee
n/a
Profits / Employee
-$3,974,667
Market Cap
1.99B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
SLNO News
- 24 days ago - Soleno Therapeutics to Participate in Upcoming February Investor Conferences - GlobeNewsWire
- 2 months ago - Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC - GlobeNewsWire
- 3 months ago - Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 3 months ago - Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome - GlobeNewsWire
- 3 months ago - Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024 - GlobeNewsWire
- 4 months ago - Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments - Seeking Alpha
- 4 months ago - SLNO Stock Rises as Prader-Willi Treatment Nears FDA Approval - GuruFocus
- 5 months ago - Janus Henderson Group PLC's Strategic Acquisition in Soleno Therapeutics Inc - GuruFocus